Curcumin is known to have antioxidant and neuroprotective effects, but it degrades too quickly in the body to make a good drug candidate. NanoCur is a compound developed from curcumin, with improved pharmacokinetic characteristics. It was developed by researchers at the University of Limoges, with the support of the AFM-Téléthon, to target nerve damage in Charcot-Marie-Tooth 1A disease.
- NanoCur was administered daily to rodent models of CMT 1A for 8 to 12 weeks.
- It improved the motor skills of treated animals through better myelination of nerve fibres,
- No toxicity was observed.
